<?xml version="1.0" ?>
<document id="546de9ee7a4ee26a482af31e1b374ee85242e0c5">
  <chunk id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c0" text="Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV">
    <entity charOffset="55-62" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c0.e0" ontology_id="CHEBI_16541" text="Protein" type="chemical"/>
  </chunk>
  <chunk id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1" text="In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our knowledge there has been no reported cases of effective antiviral antibody-peptide bispecific fusion proteins. We previously developed potent fully human monoclonal antibodies and inhibitory peptides against Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a novel coronavirus that causes severe acute respiratory illness with high mortality. Here, we describe the generation of antibody-peptide bispecific fusion proteins, each of which contains an anti-MERS-CoV single-chain antibody m336 (or normal human IgG1 CH3 domain as a control) linked with, or without, a MERS-CoV fusion inhibitory peptide HR2P. We found that one of these fusion proteins, designated as m336 diabody-pep, exhibited more potent inhibitory activity than the antibody or the peptide alone against pseudotyped MERS-CoV infection and MERS-CoV S protein-mediated cell-cell fusion, suggesting its potential to be developed as an effective bispecific immunotherapeutic for clinical use.">
    <entity charOffset="186-194" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e0" ontology_id="CHEBI_33250" text="elements" type="chemical"/>
    <entity charOffset="304-313" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e1" ontology_id="CHEBI_22587" text="antiviral" type="chemical"/>
    <entity charOffset="439-447" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e2" ontology_id="CHEBI_16670" text="peptides" type="chemical"/>
    <entity charOffset="848-855" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e3" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <entity charOffset="1005-1012" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e4" ontology_id="CHEBI_16670" text="peptide" type="chemical"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e0" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e1" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p0" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e0" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e2" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p1" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e0" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e3" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p2" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e0" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e4" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p3" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e1" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e2" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p4" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e1" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e3" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p5" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e1" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e4" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p6" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e2" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e3" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p7" relation="true"/>
    <pair e1="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e2" e2="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.e4" id="546de9ee7a4ee26a482af31e1b374ee85242e0c5.c1.p8" relation="true"/>
  </chunk>
</document>
